Safety & Immunogenicity of a 3-Antigen Hepatitis B Vaccine, PreHevbrio [Hepatitis B Vaccine (Recombinant)] Webinar

AIM was joined by VBI Vaccines Chief Medical Officer Francisco Diaz-Mitoma, MD, Ph.D., to hear an overview of their recently approved and ACIP-recommended Hepatitis B vaccine, PreHevbrio. Following the February 2022 ACIP meeting, PreHevbrio was added to the list of ACIP-recommended products for prophylactic adult vaccination against HBV infection (without a formal vote). During the webinar, Dr. Diaz-Mitoma provided an overview of safety and immunogenicity data of the PreHevbrio 3-antigen Hepatitis B vaccine and answered questions from AIM members.

Webinar Resources

Back To Top